Physician profile
Robert E Mcguire
NPI 1902824337
$1,389.76
in general payments reported to CMS, 2019-2025
13 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.40 · 2021: $323 · 2022: $154 · 2023: $370 · 2024: $187 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.94 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $332.85 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $289.77 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.48 | 2019-2021 | |
| Glaukos Corporation | $69.86 | 2023-2024 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Merz Pharmaceuticals, LLC | $52.17 | 2022-2023 | Xeomin |
| Aerie Pharmaceuticals, INC. | $35.70 | 2021 | |
| Allergan, INC. | $30.16 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $29.15 | 2022 | |
| Alcon Vision LLC | $23.99 | 2023 | Rocklatan |
| Horizon Therapeutics Plc | $20.99 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $17.12 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $15.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.